Braxia Scientific enters a new chapter as it commences trading under its new ticker “CSE: BRAX” and rebrands its growing network of leading clinics to Braxia Health, which includes the Canadian Rapid Treatment Centre of Excellence established in 2018. Only clinic in Canada previously involved in a randomized controlled pivotal trial for regulatory approval purposes of psilocybin for the treatment…


Previous articleRed Light Holland Receives Patent Pending Status For ‘Find Your Dose’ Customization of Microdosing Kits Based on Biometric and Movement Data
Next articleCan Psychedelics Provide Relief for Autistic Individuals?